S. Durant

发表

Arginine methylation regulates the p53 response

M. Jansson, N. L. Thangue, B. Kessler, 2008, Nature Cell Biology.

An assay to measure poly(ADP ribose) glycohydrolase (PARG) activity in cells

M. O’Connor, D. Ogilvie, I. Waddell, 2016, F1000Research.

Metnase promotes restart and repair of stalled and collapsed replication forks

N. Osheroff, R. Hromas, E. Williamson, 2010, Nucleic acids research.

UV Radiation Induces Delayed Hyperrecombination Associated with Hypermutation in Human Cells

J. Nickoloff, W. Morgan, G. Timmins, 2006, Molecular and Cellular Biology.

Targeting ATM for Cancer Therapy: Prospects for Drugging ATM

I. Hickson, S. Durant, K. Pike, 2018 .

Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAX

A. Hall, D. Gillespie, D. Crouch, 2003, Oncogene.

ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer

T. Pitts, J. Diamond, W. Messersmith, 2022, BMC Cancer.

Vanillins--a novel family of DNA-PK inhibitors.

P. Karran, S. Durant, 2003, Nucleic acids research.

Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors.

B. Barlaam, P. Macfaul, S. Pearson, 2018, ACS medicinal chemistry letters.

The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one).

Nichola L. Davies, B. Barlaam, S. Degorce, 2018, Journal of medicinal chemistry.

Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease.

J. Hayes, A. Dinkova-Kostova, T. Penning, 2015, Free radical biology & medicine.

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models

I. Barrett, K. Varnäs, K. Valerie, 2018, Science Advances.

ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks

A. Bradley, D. Adams, T. Stankovic, 2019, Nature Communications.

The SET domain protein Metnase mediates foreign DNA integration and links integration to nonhomologous end-joining repair.

R. Hromas, E. Williamson, J. Nickoloff, 2005, Proceedings of the National Academy of Sciences of the United States of America.

ALT neuroblastoma chemoresistance due to telomere dysfunction–induced ATM activation is reversible with ATM inhibitor AZD0156

E. Cadogan, Aaron Smith, V. Pilla Reddy, 2021, Science Translational Medicine.

ALT Neuroblastoma Chemoresistance due to ATM Activation by Telomere Dysfunction is Reversible with the ATM Inhibitor AZD0156

E. Cadogan, Aaron Smith, V. Reddy, 2021, bioRxiv.

DNA-PKcs and ATM co-regulate DNA double-strand break repair.

David J. Chen, B. Chen, J. Nickoloff, 2009, DNA repair.

ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks

Fengtang Yang, A. Bradley, D. Adams, 2018, bioRxiv.

Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models

A. Lau, D. Jodrell, Sandra Bernaldo de Quirós Fernández, 2020, British Journal of Cancer.

Structures of the Human Poly (ADP-Ribose) Glycohydrolase Catalytic Domain Confirm Catalytic Mechanism and Explain Inhibition by ADP-HPD Derivatives

J. Nissink, J. Tucker, M. McAlister, 2012, PloS one.

Telomerase-Independent Paths to Immortality in Predictable Cancer Subtypes

S. Durant, 2012, Journal of Cancer.

CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumors

Haojian Li, M. Boufraqech, E. Maier, 2022, bioRxiv.

Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice

N. Mukhopadhyay, I. Barrett, K. Valerie, 2018, Molecular Cancer Therapeutics.

ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance

E. King, J. Parsons, G. Thomas, 2022, Cancer research.

Small molecule inhibitors uncover synthetic genetic interactions of human flap endonuclease 1 (FEN1) with DNA damage response genes

P. McHugh, S. Durant, T. Ward, 2017, PloS one.

Cellular Active N-Hydroxyurea FEN1 Inhibitors Block Substrate Entry to the Active Site

J. Debreczeni, J. Nissink, L. Finger, 2016, Nature chemical biology.

p53 methylation—the Arg-ument is clear

N. L. La Thangue, E. Cho, Nicholas B La Thangue, 2009, Cell cycle.

An assay to measure poly(ADP ribose) glycohydrolase (PARG) activity in cells.

M. O’Connor, D. Ogilvie, I. Waddell, 2016, F1000Research.

Good Timing in the Cell Cycle for Precise DNA Repair by BRCA1

J. Nickoloff, S. Durant, 2005, Cell cycle.

Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes

G. Hirst, R. Borts, S. Durant, 1999, Current Biology.

Development of a High-Throughput Fluorescence Polarization DNA Cleavage Assay for the Identification of FEN1 Inhibitors

Michael Tonge, H. Plant, S. Durant, 2013, Journal of biomolecular screening.

DNA-PKcs and ATM co-regulate DNA double-strand break repair.

David J. Chen, B. Chen, J. Nickoloff, 2009, DNA repair.

H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours

M. Lopes, J. Jonkers, E. Gogola, 2023, bioRxiv.

ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis

B. Salhia, Ze Yang, K. Hurth, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.